VTI’s Interfuse is an interbody lumbar fusion system that allows for less invasive approaches to lumbar fusion operations due to smaller access channels and intra-operative assembly, the Minnetonka, Minn.-based company said.
“While our products have approval in 38 markets worldwide, China is a key market. We are excited that our technologies will be available to surgeons and patients in China,” VTI CEO Matt Kyle said in a press release.
The initial Chinese launch will take place in Hong Kong and Macau in the 4th quarter of this year, VTI said, and will follow to mainland China after the company receives regulatory approval.
“Orthopedic implants are a key area in our product portfolio and the Interfuse system offers unique benefits over other fusion products. ECM is pleased to be partnering with VTI to bring a next generation fusion implant to the China market,” ECM U.S. veep Brian Hakim, said in prepared remarks.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.